Campbell & Co Investment Adviser’s Oric Pharmaceuticals ORIC Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,815	Closed	-$378K	–	1276
2026 Q1	$378K	Buy	+29,815	New	+$338K	0.02%	823
2025 Q4	–	Sell	-13,970	Closed	-$168K	–	1332
2025 Q3	$168K	Sell	13,970 -5,698	-29%	-$59.9K	0.01%	1025
2025 Q2	$200K	Buy	+19,668	New	+$132K	0.01%	1057
2024 Q4	–	Sell	-27,241	Closed	-$279K	–	1279
2024 Q3	$279K	Buy	+27,241	New	+$269K	0.02%	928
2024 Q2	–	Sell	-96,468	Closed	-$1.33M	–	1273
2024 Q1	$1.33M	Buy	96,468 +58,849	+156%	+$699K	0.11%	279
2023 Q4	$346K	Buy	+37,619	New	+$272K	0.03%	863

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Campbell & Co Investment Adviser's ORIC Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 29,815 shares — an estimated $378K sold.

Campbell & Co Investment Adviser first reported a position in ORIC in Q4 2023 and held it in 6 quarters. The position peaked at $1.33M in Q1 2024. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 29,815 Oric Pharmaceuticals shares in Q2 2026, an estimated $378K.
Campbell & Co Investment Adviser first reported a position in Oric Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Campbell & Co Investment Adviser's Oric Pharmaceuticals position peaked at $1.33M in Q1 2024.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.